March 23, 2026: Lifeline Children’s Services is deeply concerned by reports that the Department of Justice has asked a federal court to dismiss or delay legal challenges brought by pro-life states regarding mifepristone, a key abortion drug. Filed by Texas and Florida, these cases seek to hold the FDA accountable for policies that have expanded access to chemical abortion, including distribution by mail and without in-person medical oversight.
“At a time when abortion is increasingly driven by telehealth and mail-order drugs, decisions like this risk further removing safeguards intended to protect both women and unborn children,” said Herbie Newell, president and executive director of Lifeline. “Prolonged delays that could potentially stretch through the remainder of this presidential term and into the next election cycle only deepen the harm. This is not an issue that can wait years to be resolved. With chemical abortions now accounting for a majority of procedures in the United States, even a one-year delay could mean hundreds of thousands more lives lost.”
We urge federal leaders to allow these cases to proceed and to ensure that policies surrounding abortion drugs are guided not by political calculation, but by a commitment to protecting life, upholding medical integrity, and supporting women and families. Lifeline remains steadfast in our mission to serve both mother and child through adoption, family support, and holistic, life-affirming care.
For media inquiries or to request an interview with Herbie Newell, president and executive director of Lifeline, please email pr@lifelinechild.org.
